Spotlight
Video

POLLUX & CASTOR Studies for Relapsed or Refractory Multiple Myeloma

Loading........
Description: Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexamethasone (DRd) and bortezomib plus dexamethasone in relapsed and refractory multiple myeloma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Shared By : AnnualMeeting2017
Posted on : 06/15/17
Added : 5 months ago
Category : Multiple Myeloma



Recommended

Nothing found.

More From AnnualMeeting2017

Nothing found.